Found: 18
Select item for more details and to access through your institution.
Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration.
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 6, p. 1, doi. 10.1093/ofid/ofae282
- By:
- Publication type:
- Article
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.
- Published in:
- Open Forum Infectious Diseases, 2021, v. 8, n. 9, p. 1, doi. 10.1093/ofid/ofab439
- By:
- Publication type:
- Article
884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S20, doi. 10.1093/ofid/ofz359.043
- By:
- Publication type:
- Article
Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients.
- Published in:
- AIDS Research & Treatment, 2015, v. 2015, p. 1, doi. 10.1155/2015/938628
- By:
- Publication type:
- Article
Single-dose pharmacokinetics of pediatric and adult formulations of etravirine and swallowability of the 200-mg tablet: results from three Phase 1 studies.
- Published in:
- International Journal of Clinical Pharmacology & Therapeutics, 2013, v. 51, n. 9, p. 725, doi. 10.5414/CP201770
- By:
- Publication type:
- Article
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
- Published in:
- Patient, 2021, v. 14, n. 6, p. 849, doi. 10.1007/s40271-021-00524-0
- By:
- Publication type:
- Article
Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies.
- Published in:
- Antiviral Therapy, 2021, v. 26, n. 6-8, p. 95, doi. 10.1177/13596535211062388
- By:
- Publication type:
- Article
Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C.
- Published in:
- Annals of Hepatology: Official Journal of the Mexican Association of Hepatology, 2016, v. 15, n. 4, p. 512, doi. 10.5604/16652681.1202922
- By:
- Publication type:
- Article
Asian participants' experience in phase 3/3b studies of long‐acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96.
- Published in:
- HIV Medicine, 2024, v. 25, n. 3, p. 381, doi. 10.1111/hiv.13588
- By:
- Publication type:
- Article
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long‐acting cabotegravir and rilpivirine in clinical trials.
- Published in:
- HIV Medicine, 2023, v. 24, n. 5, p. 568, doi. 10.1111/hiv.13439
- By:
- Publication type:
- Article
Compassionate use of long‐acting cabotegravir plus rilpivirine for people living with HIV‐1 in need of parenteral antiretroviral therapy.
- Published in:
- HIV Medicine, 2023, v. 24, n. 2, p. 202, doi. 10.1111/hiv.13370
- By:
- Publication type:
- Article
Long-Acting Cabotegravir+Rilpivirine Injection Site Reactions: Pooled Week 96 Results.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. 277
- By:
- Publication type:
- Article
Safety profile of cabotegravir + rilpivirine during oral lead-in and through long-acting therapy: pooled analysis of the phase 3 FLAIR, ATLAS, and ATLAS-2M studies.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. S304
- By:
- Publication type:
- Article
Pharmacokinetics of bound and unbound telaprevir in cirrhotic patients with moderate and severe hepatic impairment.
- Published in:
- Journal of Clinical Pharmacology, 2015, v. 55, n. 10, p. 1147, doi. 10.1002/jcph.545
- By:
- Publication type:
- Article
The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.
- Published in:
- Journal of Clinical Pharmacology, 2014, v. 54, n. 4, p. 422, doi. 10.1002/jcph.214
- By:
- Publication type:
- Article
Pharmacokinetics and Short-Term Safety of Etravirine in Combination With Fluconazole or Voriconazole in HIV-Negative Volunteers.
- Published in:
- Journal of Clinical Pharmacology, 2013, v. 53, n. 1, p. 41, doi. 10.1177/0091270011433329
- By:
- Publication type:
- Article
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 9, p. 1646, doi. 10.1093/cid/ciad020
- By:
- Publication type:
- Article
Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.
- Published in:
- Journal of Infectious Diseases, 2024, v. 230, n. 1, p. e34, doi. 10.1093/infdis/jiad580
- By:
- Publication type:
- Article